GlobeNewswire: Galectin Therapeutics Inc. Contains the last 10 of 251 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T12:30:53ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/29/2854716/0/en/Galectin-Therapeutics-Reports-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=19821Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update2024-03-29T12:00:00Z<![CDATA[NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023.]]>https://www.globenewswire.com/news-release/2024/03/12/2844466/0/en/Galectin-Therapeutics-Expands-Clinical-Team-with-the-Appointment-of-Khurram-Jamil-M-D-as-Vice-President-Clinical-Development.html?f=22&fvtc=4&fvtv=19821Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development2024-03-12T12:00:00Z<![CDATA[NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D. as Vice President, Clinical Development. Dr. Jamil brings to Galectin almost two decades of experience in clinical development across the biotechnology industry.]]>https://www.globenewswire.com/news-release/2023/11/13/2779087/0/en/UPDATE-Galectin-Therapeutics-Reports-Financial-Results-for-the-Quarter-Ended-September-30-2023-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=19821UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update2023-11-13T13:45:52Z<![CDATA[NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2023. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov.]]>https://www.globenewswire.com/news-release/2023/11/13/2778990/0/en/Galectin-Therapeutics-Reports-Financial-Results-for-the-Quarter-Ended-September-30-2023-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=19821Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update2023-11-13T13:00:00Z<![CDATA[NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2023. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov.]]>https://www.globenewswire.com/news-release/2023/11/03/2773132/0/en/Galectin-Therapeutics-to-Share-Five-Scientific-Presentations-at-The-Liver-Meeting-2023-Hosted-by-the-AASLD.html?f=22&fvtc=4&fvtv=19821Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD2023-11-03T12:00:00Z<![CDATA[NORCROSS, Ga., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will share five scientific presentations at The Liver Meeting™ 2023, hosted by the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting™ will be held November 10-14, 2023, in Boston, Mass.]]>https://www.globenewswire.com/news-release/2023/10/23/2764657/0/en/Galectin-Therapeutics-to-Participate-in-the-H-C-Wainwright-7th-Annual-NASH-Investor-Conference-on-October-24-2023.html?f=22&fvtc=4&fvtv=19821Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 20232023-10-23T12:00:00Z<![CDATA[NORCROSS, Ga., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 7th Annual NASH Investor Conference being held virtually on October 24, 2023.]]>https://www.globenewswire.com/news-release/2023/10/12/2759166/0/en/Galectin-Therapeutics-Announces-Nomination-of-Dr-Benjamin-S-Carson-Sr-to-Board-of-Directors.html?f=22&fvtc=4&fvtv=19821Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors2023-10-12T12:00:00Z<![CDATA[NORCROSS, Ga., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Benjamin S. Carson, Sr. has been nominated to serve on the company’s board of directors.]]>https://www.globenewswire.com/news-release/2023/10/03/2753579/0/en/Galectin-Therapeutics-Reports-the-Positive-Outcome-of-the-Fourth-Data-and-Safety-Monitoring-Board-Meeting-for-NAVIGATE-its-Seamless-Adaptive-Phase-2b-3-Study-of-Belapectin-in-Patie.html?f=22&fvtc=4&fvtv=19821Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis2023-10-03T12:00:00Z<![CDATA[NORCROSS, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its fourth data and safety monitoring board (DSMB) meeting for NAVIGATE, its seamless, adaptive, Phase 2b/3 study of belapectin in patients with portal hypertension caused by non-alcoholic steatohepatitis (NASH) liver cirrhosis. NAVIGATE is the first study of its kind and is a global effort that randomized 357 patients in 14 countries on five continents. The main efficacy objective is the primary prevention of esophageal varices. Interim topline data from the Phase 2b portion of NAVIGATE is expected in the fourth quarter of 2024.]]>https://www.globenewswire.com/news-release/2023/09/26/2749392/0/en/Galectin-Therapeutics-to-Present-Update-on-its-Belapectin-Liver-Cirrhosis-Program-at-the-20th-Edition-of-Discovery-on-Target-meeting-in-Boston-September-25-28-2023.html?f=22&fvtc=4&fvtv=19821Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 20232023-09-26T12:00:00Z<![CDATA[NORCROSS, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today announced it will participate in the 20th edition of the Discovery on Target meeting, the industry’s preeminent event on Novel Drug Targets and Technologies. The Company will present an update on its belapectin liver cirrhosis program during the Fibrosis and Inflammation session. The presentation, titled “Targeting Activated Macrophages to Improve Liver Cirrhosis: The Discovery and Clinical Translation of Belapectin,” will take place Wednesday, September 27, at 2:25 PM EDT and will be delivered by Dr. Pol F. Boudes, M.D., Chief Medical Officer of Galectin Therapeutics.]]>https://www.globenewswire.com/news-release/2023/09/13/2742903/0/en/Galectin-Therapeutics-to-Participate-in-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference-on-September-13-2023.html?f=22&fvtc=4&fvtv=19821Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 20232023-09-13T21:22:16Z<![CDATA[NORCROSS, Ga., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11-13, 2022. The Wainwright Conference – which takes place at the Lotte New York Palace Hotel in New York City, New York – brings together thought leaders and practitioners from numerous fields to participate in presentations, one-on-one investor meetings, and networking opportunities with other attendees.]]>